

## Appendix 3Y

### Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Mayne Pharma Group Limited</b>
<b>ABN</b>	<b>76 115 832 963</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Scott Anthony Richards
<b>Date of last notice</b>	9 Jan 2020

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Solium Nominees (Australia) Pty Ltd <Bare Allocated A/C> as nominee for Scott Richards (1) HSBC Nominees (Australia) Limited as nominee for Scott Anthony Richards (2) HSBC Nominees (Australia) Limited as nominee for Scott Anthony Richards & Susan Marie Richards <Northumberland Trust> (3)
<b>Date of change</b>	31 Aug 2020
<b>No. of securities held prior to change</b>	22,779,411 Ordinary Shares pursuant to Executive Share Loan Scheme (1) 3,862,906 Ordinary Shares (2) 1,722,463 Ordinary Shares (3) 2,555,805 Performance Rights pursuant to Performance Right and Option Plan
<b>Class</b>	Ordinary Shares
<b>Number acquired</b>	Nil
<b>Number disposed</b>	2,553,496
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Not Applicable. Forfeit of employee loan shares pursuant to the Executive Share Loan Scheme.

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	20,225,915 Ordinary Shares pursuant to Executive Share Loan Scheme (1) 3,862,906 Ordinary Shares (2) 1,722,463 Ordinary Shares (3) 2,555,805 Performance Rights pursuant to Performance Right and Option Plan
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Forfeit of employee loan shares pursuant to the Executive Share Loan Scheme.

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

#### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/a
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/a
<b>If prior written clearance was provided, on what date was this provided?</b>	N/a

<sup>+</sup> See chapter 19 for defined terms.